2.65

7.02% -0.20

After Hours: 2.55 -0.10 -3.77%

Onkure Therapeutics Inc (OKUR)

Overview News Price History Discussions Forecast

Onkure Therapeutics Inc stock is traded at $2.65, with a volume of 164.92K. It is down -7.02% in the last 24 hours and up +44.02% over the past month. OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. The company operates in one operating segment which is clinical research. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.

Previous Close:

$2.85

Open:

$2.81

24h Volume:

164.92K

Relative Volume:

1.15

Market Cap:

$38.91M

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

-7.99%

1M Performance:

+44.02%

6M Performance:

-73.12%

1Y Performance:

+0.00%

1-Day Range:

$2.52

$2.89

1-Week Range:

$2.52

$3.1497

52-Week Range:

$1.70

$19.40

Onkure Therapeutics Inc Stock (OKUR) Company Profile

Name

Onkure Therapeutics Inc

Sector

Healthcare (1168)

Industry

Biotechnology (661)

Phone

(720) 307-2892

Address

6707 WINCHESTER CIRCLE, SUITE 400, BOULDER

Employee

Twitter

Next Earnings Date

2024-11-11

Latest SEC Filings

OKUR's Discussions on Twitter

Compare OKUR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
OKUR Onkure Therapeutics Inc	2.65	38.91M	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	455.45	115.69B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	529.24	53.25B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	307.99	39.22B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	577.89	35.78B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	269.63	27.68B	3.81B	-644.79M	-669.77M	-6.24

Onkure Therapeutics Inc Stock (OKUR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-30-25	Initiated	Evercore ISI	Outperform
Dec-05-24	Initiated	Leerink Partners	Outperform
Oct-10-24	Initiated	Oppenheimer	Outperform
Dec-15-23	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-15-23	Downgrade	Jefferies	Buy → Hold
Dec-15-23	Downgrade	Leerink Partners	Outperform → Market Perform
Dec-14-23	Downgrade	BofA Securities	Buy → Underperform
Dec-14-23	Downgrade	Ladenburg Thalmann	Buy → Neutral
Dec-14-23	Downgrade	Piper Sandler	Overweight → Neutral
Dec-14-23	Downgrade	Robert W. Baird	Outperform → Neutral
Dec-14-23	Downgrade	William Blair	Outperform → Mkt Perform
Nov-15-23	Initiated	William Blair	Outperform
Aug-28-23	Initiated	H.C. Wainwright	Buy
Jul-03-23	Initiated	BofA Securities	Buy
Sep-19-22	Resumed	H.C. Wainwright	Buy
Jan-27-22	Initiated	Robert W. Baird	Outperform
Dec-21-21	Initiated	H.C. Wainwright	Buy
Nov-22-21	Initiated	Ladenburg Thalmann	Buy
May-04-21	Initiated	Jefferies	Buy
May-04-21	Initiated	Piper Sandler	Overweight
May-04-21	Initiated	SVB Leerink	Outperform

View All

Onkure Therapeutics Inc Stock (OKUR) Latest News

Jun 08, 2025

Two Sigma Advisers LP Invests $122,000 in OnKure Therapeutics (NASDAQ:OKUR) - Defense World

Jun 08, 2025

Jun 05, 2025

Millennium Management LLC Acquires New Shares in OnKure Therapeutics (NASDAQ:OKUR) - Defense World

Jun 05, 2025

Jun 04, 2025

Northern Trust Corp Purchases New Position in OnKure Therapeutics (NASDAQ:OKUR) - Defense World

Jun 04, 2025

Jun 03, 2025

Buy Rating for OnKure Therapeutics Driven by Promising Developments in Metastatic Breast Cancer Treatment and Strong Financial Position - TipRanks

Jun 03, 2025

Bank of America Corp DE Takes $2.15 Million Position in OnKure Therapeutics (NASDAQ:OKUR) - Defense World

Jun 03, 2025

May 28, 2025

OnKure Elects Directors at Annual Stockholder Meeting - TipRanks

May 28, 2025

May 25, 2025

OnKure Therapeutics (NASDAQ:OKUR) Given Consensus Recommendation of “Buy” by Analysts - Defense World

May 25, 2025

May 19, 2025

Major Stakeholders Shuffle Shares in OnKure Therapeutics - TipRanks

May 19, 2025

May 17, 2025